Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Binacea Pharma
Hayward, California, United Statesbinaceapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting a Phase 1 dose escalation study (NCT05150457) to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of BNA035 in patients with advanced solid tumors. The study aims to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D).
- Therapeutic areas
- OncologyImmunology
- Modalities
- Antibody drugsBispecific antibodiesNanobody
- Industry
- Biotech
02
Partnerships
Henlius Biotech (licensed HLX35, an anti-EGFR and anti-4-1BB bispecific antibody)
Beyond the preview
Go deeper on Binacea Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Binacea Pharma.